Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Paclitaxel, Cisplatin\Carboplatin With Toripalimab and Anlotinib for First Line Treatment of Advanced Cervical Cancer

NCT04731038 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT04731038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04731038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Paclitaxel, Cisplatin\Carboplatin With Toripalimab and Anlotinib for First Line Treatment of Advanced Cervical Cancer
Lead sponsor
Ruijin Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
August 1, 2021
Completion date
July 1, 2024
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cervical cancer